IHI - ETF AI Analysis
Top Page
iShares U.S. Medical Devices ETF (IHI)
Rating:74Outperform
Price Target:―
Positive Factors
Focused Exposure to Medical Devices
The fund gives investors targeted access to the U.S. medical devices industry, which can benefit from long-term trends like an aging population and growing healthcare demand.
Large, Established Companies in Top Holdings
Many of the biggest positions are well-known, mature healthcare companies, which can offer more stability than smaller, unproven firms.
Single-Country Simplicity
With almost all assets in U.S. companies, investors avoid the added complexity of currency swings and foreign market risks.
Negative Factors
High Concentration in a Few Stocks
A small number of holdings make up a large share of the portfolio, so problems at those companies could have a big impact on the ETF.
Recent Weak Performance
The fund has shown weak results so far this year and over the past few months, which may concern investors looking for steady returns.
Heavy Sector and Country Concentration
Almost all assets are in U.S. healthcare stocks, so the ETF is highly sensitive to downturns in this single sector and market.
IHI vs. SPDR S&P 500 ETF (SPY)
AUM3.48B
RegionNorth America
Expense Ratio0.37%
Beta0.65
IssueriShares
Inception DateMay 01, 2006
Dividend Yield0.51%
Asset ClassEquity
Index TrackedDJ US Select / Medical Equipment
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,687,171
30 Day Avg. Volume2,880,370
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
62.96Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering45
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IHI Summary
The iShares U.S. Medical Devices ETF (IHI) is a fund that follows the DJ US Select / Medical Equipment index, focusing on U.S. companies that make medical tools and devices used in hospitals and clinics. It holds well-known names like Abbott Laboratories and Intuitive Surgical, along with other leaders in surgical equipment, diagnostics, and patient monitoring. Someone might invest in IHI to tap into the long-term growth of healthcare technology and to diversify within the medical sector. A key risk is that it is heavily concentrated in healthcare devices, so its value can rise or fall sharply with that specific industry.
How much will it cost me?The iShares U.S. Medical Devices ETF (IHI) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically involves more specialized management compared to broad-market passive funds.
What would affect this ETF?The iShares U.S. Medical Devices ETF (IHI) could benefit from growing demand for advanced healthcare solutions and technological innovations in medical devices, driven by an aging population and increased focus on personalized medicine. However, potential risks include regulatory changes, pricing pressures, and economic downturns that may impact healthcare spending, as well as competition among top holdings like Abbott Laboratories and Intuitive Surgical. The ETF’s focus on U.S.-based companies may also limit exposure to growth opportunities in international markets.
IHI Top 10 Holdings
IHI is essentially a bet on U.S. medical-device heavyweights, with Abbott, Intuitive Surgical, and Stryker steering the ship. Abbott has been rising lately, helping to offset earlier softness, while Intuitive Surgical’s mixed recent performance and Stryker’s choppy trading have kept returns from really breaking out. On the brighter side, Dexcom and Becton Dickinson have been climbing, giving the fund a boost from growthier names. With nearly all holdings in U.S. healthcare equipment, this ETF is tightly focused on one niche rather than spreading its bets globally.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Abbott Laboratories | 18.17% | $646.63M | $177.12B | -23.71% | 73 Outperform | |
| Intuitive Surgical | 13.80% | $491.07M | $135.05B | -12.00% | 78 Outperform | |
| Stryker | 10.01% | $356.32M | $109.23B | -25.86% | 70 Outperform | |
| Becton Dickinson | 5.29% | $188.20M | $49.53B | -3.71% | 67 Neutral | |
| Dexcom | 4.96% | $176.70M | $32.96B | 14.26% | 79 Outperform | |
| Medtronic | 4.96% | $176.49M | $118.45B | -2.95% | 80 Outperform | |
| Resmed | 4.88% | $173.58M | $32.93B | -15.99% | 76 Outperform | |
| Edwards Lifesciences | 4.46% | $158.83M | $51.46B | 18.38% | 79 Outperform | |
| GE Healthcare Technologies Inc | 4.25% | $151.42M | $28.68B | -14.20% | 78 Outperform | |
| Idexx Laboratories | 3.96% | $141.03M | $40.46B | -19.85% | 78 Outperform |
IHI Technical Analysis
Negative
―
Price Trends
53.07
Negative
51.41
Positive
54.89
Negative
Market Momentum
-0.67
Positive
40.20
Neutral
38.17
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 53.34, equal to the 50-day MA of 53.07, and equal to the 200-day MA of 54.89, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 38.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IHI.
IHI Peer Comparison
Comparison Results
Performance Comparison
IHI
iShares U.S. Medical Devices ETF
51.77
-8.27
-13.77%
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents